Literature DB >> 17877537

The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci.

Sally A DuPré1, Doug Redelman, Kenneth W Hunter.   

Abstract

The murine mammary carcinoma 4T1 causes a leukemoid reaction with profound granulocytosis coincident with the production of tumour-derived growth factors. Here, we study the evolving cellular landscape of primary tumours and metastatic tumour foci and correlate haematopoietic cell infiltration with the production of tumour-derived chemokines. Flow cytometric analysis of enzyme digested primary tumours at different times after transplantation revealed a progressively increasing CD45(+) haematopoietic cell infiltrate consisting predominantly of CD11b(+) myeloid cells. Most of these cells had an F4/80(+)/CD11c(+) phenotype, many of which also stained Gr-1(+). Smaller numbers of Gr-1(+)CD11b(+) granulocytes and lymphoid cells were also identified. Progressive increases in Gr-1(+) granulocytes were observed in enzymatic digests of livers and lungs with metastatic tumour foci. Cultured 4T1 tumour cells expressed mRNA transcripts for the myeloid cell chemokines RANTES, MCP-1 and KC, and enzymatically digested cells from primary 4T1 tumours partially depleted of CD45(+) cells expressed transcripts for these chemokines and also MIP-1alpha and MIP-1beta. These data demonstrate that 4T1 tumour-bearing mice have mixed myeloid cell infiltrates of primary tumours and granulocytic infiltrates of metastatic organs. This pathologic presentation correlated with the expression of tumour-derived chemokines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17877537      PMCID: PMC2517332          DOI: 10.1111/j.1365-2613.2007.00539.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  38 in total

Review 1.  The intriguing role of polymorphonuclear neutrophils in antitumor reactions.

Authors:  E Di Carlo; G Forni; P Lollini; M P Colombo; A Modesti; P Musiani
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

2.  Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism.

Authors:  B Peláez; J A Campillo; J A López-Asenjo; J L Subiza
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

3.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

4.  Human neutrophils facilitate tumor cell transendothelial migration.

Authors:  Q D Wu; J H Wang; C Condron; D Bouchier-Hayes; H P Redmond
Journal:  Am J Physiol Cell Physiol       Date:  2001-04       Impact factor: 4.249

5.  Chemokine receptor desensitization in tumor-bearing mice.

Authors:  R A Kurt; A Baher; K P Wisner; S Tackitt; W J Urba
Journal:  Cell Immunol       Date:  2001-02-01       Impact factor: 4.868

Review 6.  Nontransgenic models of breast cancer.

Authors:  G H Heppner; F R Miller; P M Shekhar
Journal:  Breast Cancer Res       Date:  2000-08-04       Impact factor: 6.466

7.  Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Authors:  B Almand; J I Clark; E Nikitina; J van Beynen; N R English; S C Knight; D P Carbone; D I Gabrilovich
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

8.  Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice.

Authors:  I Angulo; F G de las Heras; J F García-Bustos; D Gargallo; M A Muñoz-Fernández; M Fresno
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

9.  Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family.

Authors:  T J Fleming; M L Fleming; T R Malek
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

Review 10.  Inflammatory cells and cancer: think different!

Authors:  L M Coussens; Z Werb
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  76 in total

1.  An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Authors:  Zachary C Hartman; Junping Wei; Takuya Osada; Oliver Glass; Gangjun Lei; Xiao-Yi Yang; Sharon Peplinski; Dong-Wan Kim; Wenle Xia; Neil Spector; Jeffrey Marks; William Barry; Amy Hobeika; Gayathri Devi; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Thymic stromal lymphopoietin is a key mediator of breast cancer progression.

Authors:  Purevdorj B Olkhanud; Yrina Rochman; Monica Bodogai; Enkhzol Malchinkhuu; Katarzyna Wejksza; Mai Xu; Ronald E Gress; Charles Hesdorffer; Warren J Leonard; Arya Biragyn
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

3.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

4.  Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.

Authors:  Christine Mall; Gail D Sckisel; David A Proia; Annie Mirsoian; Steven K Grossenbacher; Chien-Chun Steven Pai; Mingyi Chen; Arta M Monjazeb; Karen Kelly; Bruce R Blazar; William J Murphy
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

5.  Tumor entrained neutrophils inhibit seeding in the premetastatic lung.

Authors:  Zvi Granot; Erik Henke; Elizabeth A Comen; Tari A King; Larry Norton; Robert Benezra
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

6.  Innate and adaptive immunity combined for cancer treatment.

Authors:  Sebastian Kobold
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

7.  Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.

Authors:  Monica Bodogai; Kanako Moritoh; Catalina Lee-Chang; Christine M Hollander; Cheryl A Sherman-Baust; Robert P Wersto; Yoshihiko Araki; Ichiro Miyoshi; Li Yang; Giorgio Trinchieri; Arya Biragyn
Journal:  Cancer Res       Date:  2015-07-16       Impact factor: 12.701

8.  Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.

Authors:  Stephen Iwanowycz; Junfeng Wang; Johnie Hodge; Yuzhen Wang; Fang Yu; Daping Fan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

9.  Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.

Authors:  Shaojin You; Lian Zuo; Wei Li
Journal:  Int J Nanomedicine       Date:  2010-04-07

10.  Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

Authors:  Christina L Roland; Kristi D Lynn; Jason E Toombs; Sean P Dineen; D Gomika Udugamasooriya; Rolf A Brekken
Journal:  PLoS One       Date:  2009-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.